Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05941793 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients
A Phase 2 study of Mild to Moderate COVID-19, sponsored by Oneness Biotech Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
- 5
- Study locations
NCT05941793: Completed Phase 2 study of Mild to Moderate COVID-19, sponsored by Oneness Biotech Co..
NCT05941793 is a Phase 2 study of Mild to Moderate COVID-19 that has completed, run by Oneness Biotech Co.. The registered enrollment target is 135 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05941793, a Phase 2 study of Mild to Moderate COVID-19, has completed, sponsored by Oneness Biotech Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants with Mild to Moderate COVID-19
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MBS-COV
Study Locations (5)
Other
- Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare - New Taipei City
- National Taiwan University Hospital - Taipei
- Taipei Medical University Hospital - Taipei
- Taipei Municipal Wanfang Hospital - Taipei
Utah
- Velocity Clinical Research - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2024-08-12 |
| Phase | Phase 2 |
What the finished NCT05941793 record still lists
NCT05941793 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Mild to Moderate COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05941793 lists 5 locations in 2 states (Other, Utah).
Frequently Asked Questions
What is clinical trial NCT05941793 about?
NCT05941793 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients". A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants with Mild to Moderate COVID-19
What is the current status of trial NCT05941793?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2023-09-11. Estimated completion is 2024-08-12.
What conditions does trial NCT05941793 study?
This clinical trial studies the following conditions: Mild to Moderate COVID-19.
What interventions are being tested in trial NCT05941793?
The interventions under investigation include: Placebo (DRUG), MBS-COV (DRUG).
Who is sponsoring clinical trial NCT05941793?
This trial is sponsored by Oneness Biotech Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05941793 being conducted?
This trial has 5 study locations across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05941793's enrollment target sits among peer trials
135 532nd of 2000 higher than 1,464 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI